Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Thrombotargets Corporation Launches BioPlatformScreen™ Service
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Thrombotargets has developed and adapted to high throughput screening named BioPlatformScreen™ that change completely the concept of HTS Service.
According to Company, these new family of biological assays are capable to quantify simultaneously clot formation and clot lysis (Hemosta-BioplatformScreen™), total antioxidant capacity (Oxidant-BioplatformScreen™) and low-density lipoprotein modification (Athero-BioplatformScreen™).
